Research programme: therapeutic proteins - TheraPten
Alternative Names: TPT-612; TPT-612/ES; TPT-612/GBM; TPT-612/MM; TPT-612/RCC; TPT-612/TNBC; TPT-612/X; TPT-613; TPT-613/TNBCLatest Information Update: 28 May 2021
At a glance
- Originator TheraPten Biosciences
- Developer National Research Council Canada; TheraPten Biosciences
- Class Antineoplastics; Tumour suppressor proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours